Sovremennye podkhody k sistemnomu lekarstvennomu lecheniyu metastazov v kosti zlokachestvennykh opukholey
- Authors: Manzyuk L.V1
-
Affiliations:
- Issue: No 17 (2013)
- Pages: 15-19
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282500
- ID: 282500
Cite item
Open Access
Access granted
Abstract
The present review is dedicated to the effectiveness of modern therapy of bone metastases. Bisphosphonates, zoledronic acid and denosumab are compared. Results of clinical studies in patients with breast cancer, lung cancer and prostate cancer are presented. A number of large studies that confirmed efficacy of denosumab in many malignant tumors and its advantage over zoledronic acid in the prevention of bone complications and improving the quality of life of patients with breast cancer, lung cancer and prostate cancer are described.
Keywords
Full Text
References
- Jemal A, et al. Cancer statistics. Cancer J Clin 2009;59:225-49.
- Dougall WC, Chaisson M. The RANK/RANKL/ OPG triad in cancer-induced bone diseases. Cancer Met Rev 2206;25:541-49.
- Lacey DL, et al. Osteoprotogerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
- Martin TJ. Paracrine regulation of osteoclast formation and activity: milestones in discovery. J Musculoskelet Neuronal Interact 2004; 4:243-53.
- Roodman GD. Mechanisms of bone metastases. N Engl J Med 2004;350:1655-64.
- Costa L, et al. Impact of skeletal complications on patients quality of life, mobility, and functional independence. Support Care Cancer 2008;16:879-89.
- Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
- Coleman RE. Bisphosphonates: Clinical experience. Oncologist. 2004;9(4):14-27.
- Fleisch H. Bisphosphonates: Mechanisms of action Endocr Rev 1998;19:80-100.
- Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009;6:163-74.
- Pavlakis N, et al. Cochrane Detabasy Syst Rev. 3:CD Bisphosphonates for breast cancer. 2005;003474.
- Gralow JR, et al. NCCN Task Force Report:Bone health in cancer care J Natl Compr Netw 2009;7:1-32.
- Murthy RK, et al. Bone biology and role of the RANK ligand pathway Oncology 2009;23:9-15.
- Demers LM, et al. Jf Biochemical markers and skeletal metastases. Cancer 2000:2919-26.
- Body JJ, et al. Rapid, profound and prolonged suppression of bone turnover with a single SC dose of AMG162 in women with breast cancer metastatic to bone. J Bone Mineral Res 2004;19:1593.
- Lipton A, et al. Randomised, active-controlled phase 2 study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-37.
- Peterson MC, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of AMG162, a fully human monoclonal antipbody to receptor activator NF kappa-B ligand (RANKL) in patients with cancer-related bone lesions. J Clin Onc 2004;22(14):8106.
- Fizazi K, et al. Randomized phase II trial of denosumab in patient with Bone metastases from prostate cancer, breast cancer, or other neoplasms after i.v.bisphosphonates. J Clin Oncol 2009;27:1564-71.
- Lipton A, et al. Comparison of Denosumab Versus Zoledronic Acid for Treatment of Bone Metastases in Advanced Cancer Patients: An Integrated Analysis of 3 Pivotal Trials Ann Oncol 2010;21(8):379.
- Scagliotti GV, et al. Overall Survival improvement in Patiente with Lung Cancer and Bone Metastases Treated with Denosumab versus Zoledronic Acid J Thoracic Oncol 2012;12(7):1823-29.
- Miller RE, et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor, burden in a murine model of prostate cancer bone Metastatis. Cancer Ther 2008; 7:2160-69.
Supplementary files
